Malik A, et al. - Researchers evaluated the impact of neo-adjuvant chemotherapy (NACT) on patients with head and neck squamous cell carcinoma (HNSCC) and advanced unresectable cervical nodal metastasis. They conducted a retrospective cohort study to assess the response of unresectable nodes to NACT in a pragmatic manner. They noted probable utilization of NACT in HNSCC with advanced inoperable nodal disease to make them amenable to definitive therapy. They noted 24, 13, 10 and 9 months, respectively, to be the overall survival of patients undergoing surgery, definitive chemoradiotherapy, palliative chemotherapy and palliative radiotherapy.